|
|
|
|
LCA
|
see Leber Congenital Amaurosis
|
|
|
Leber Congenital Amaurosis (LCA)
|
Leber congenital amaurosis (LCA) is an inherited retinal degenerative disease characterized by severe loss of vision at birth. A variety of other eye-related abnormalities including roving eye movements, deep-set eyes, and sensitivity to bright light also occur with this disease. Some patients with LCA also experience central nervous system abnormalities.
|
|
|
Lens
|
The transparent part of the eye that focuses light onto the retina, so that we can see. |
|
|
Locus (plural, Loci)
|
A locus is the chromosomal "neighborhood" where a gene (a "house") resides; specifically, a potential disease-causing gene.
|
|
|
LucentisĀ®
|
A blood vessel growth-blocking drug approved by the FDA in June 2006 for treatment of wet AMD.
|
|
|
Lutein and Zeaxanthin
|
Nutrient pigments chemically related to beta-carotene that are abundant in green leafy vegetables and yellow and orange-colored fruits and vegetables. These are the only two known food pigments that collect in the macula, where they are thought to protect it from light damage (blue light).
|
|
|
MacugenĀ®
|
An anti-VEGF drug approved by the FDA in 2004 for treatment of wet AMD.
|
|
|
Macula
|
The center of the retina that has a concentration of cone photoreceptor cells and is responsible for fine detail, day and color vision.
|
|
|
Messenger RNA (mRNA)
|
The processed gene "messenger" (derived from DNA) that is the template for making proteins. Also, see RNA.
|
|
|
Metabolic process
|
A series of pathways the body uses, both to break down nutrients into simple energy packets and to create building blocks that then build-up cell components and help the body to function.
|
|
|
Mutation
|
A change or "spelling mistake" in the DNA of a gene that can cause a disease (but sometimes does not cause disease).
|
|
|
NE
|
see Nutritional and Environmental Therapy
|
|
|
NEI
|
Acronym for the National Eye Institute, a part of the research-funding government organization, the United States (US) National Institutes of Health.
|
|
|
Neuroprotective Therapy (NP)
|
Delivering a protein or drug to the eye that prevents the photoreceptors and/or RPE cells from dying, thus saving vision.
|
|
|
NP
|
see Neuroprotective Therapy
|
|
|
Nucleus
|
The specialized compartment within a cell that houses the DNA.
|
|
|
Nutritional and Environmental Therapy (NE)
|
A clinically-tested nutritional supplement or lifestyle change that has been proven to slow or stop the loss of vision in a retinal degenerative disease.
|
|
|
Nystagmus
|
Nystagmus is a constant, rapid and involuntary oscillation of the eyes - one of the symptoms that can be experienced by individuals who have a retinal degenerative disease, like Leber congenital amaurosis.
|
|
|
Omega-3 fatty acid
|
A type of fat that is important for cell function. Also, see DHA.
|
|
|
Optic Nerve
|
The bundle of nerve cells, or "cable," that transmits signals from the retina to the visual processing center of the brain.
|
| |
|
Page 4 of 7 |